UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1943-01-01

Employees: 8.1K

Market Cap: -

Website: http://www.utsouthwestern.edu

Clinical Trials

A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)

Phase 2

Recruiting

Conditions: Unknown Primary Cancer
Head and Neck Squamous Cell Carcinoma
Head and Neck Cancer

Interventions: Drug: Pegsitacianine

First Posted Date: 2022-10-13

Last Posted Date: 2024-05-09

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 40

Registration Number: NCT05576974

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

Mindfulness and Yoga Therapy for Acute Pain in Sickle Cell Disease

Not Applicable

Completed

Conditions: Sickle Cell Disease
Sickle Cell Crisis

Interventions: Behavioral: Mindfulness meditation, breathing exercises (including incentive spirometry), and yoga therapy

First Posted Date: 2022-10-07

Last Posted Date: 2023-02-13

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 39

Registration Number: NCT05572294

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

Cognitive Outcomes of Brain Stimulation As a Later-in-Life Treatment

Not Applicable

Recruiting

Conditions: Dementia
Mild Cognitive Impairment
Amnestic Mild Cognitive Impairment - aMCI

Interventions: Device: NeuroElectric StarStim
Device: Sham Treatment

First Posted Date: 2022-10-03

Last Posted Date: 2024-08-12

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 9999

Registration Number: NCT05564715

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

LOcoregional Vs Systemic Therapy in Patients with BCLC Stage B HCC

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Atezolizumab and bevacizumab
Radiation: transarterial chemoembolization (TACE) or transarterial radioembolization (TARE

First Posted Date: 2022-09-13

Last Posted Date: 2024-10-03

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 204

Registration Number: NCT05537402

Locations: 🇺🇸
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States

Furoscix in Heart Failure Patients With Diuretic Resistance

Phase 2

Completed

Conditions: Heart Failure

Interventions: Combination Product: Furoscix
Drug: Diuretic Therapy

First Posted Date: 2022-09-06

Last Posted Date: 2024-12-17

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 70

Registration Number: NCT05528588

Locations: 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States

Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)

Phase 1

Recruiting

Conditions: Spasticity, Muscle
Microcephaly
Spastic Paraplegia
Intellectual Deficiency
Growth Retardation
SPG50

Interventions: Biological: MELPIDA

First Posted Date: 2022-08-26

Last Posted Date: 2024-10-08

Lead Sponsor: Elpida Therapeutics SPC

Target Recruit Count: 4

Registration Number: NCT05518188

Locations: 🇺🇸
Children's Medical Center Dallas, Dallas, Texas, United States

Polypill in Acute Coronary Syndrome

Phase 2

Recruiting

Conditions: Lipid Disorder
Coronary Artery Disease
Acute Coronary Syndrome

Interventions: Drug: Polypill
Drug: Usual Care (individual medications prescribed by primary cardiologist)

First Posted Date: 2022-08-25

Last Posted Date: 2024-12-17

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 120

Registration Number: NCT05514938

Locations: 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States

Fractionated 1927nm Laser for Hyperpigmentation in Fitzpatrick Skin Phototypes V and VI

Not Applicable

Active, not recruiting

Conditions: Hyperpigmentation

Interventions: Device: MOXI

First Posted Date: 2022-08-09

Last Posted Date: 2024-10-10

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 20

Registration Number: NCT05493280

Locations: 🇺🇸
UT Southwestern Medical Center- Dept of Plastic Surgery, Dallas, Texas, United States

Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation

Phase 4

Recruiting

Conditions: Transthyretin Cardiac Amyloidosis

Interventions: Drug: Tafamidis 61 MG

First Posted Date: 2022-08-05

Last Posted Date: 2024-11-22

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 25

Registration Number: NCT05489523

Locations: 🇺🇸
Cedars-Sinai, Beverly Hills, California, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States

Radiofrequency Ablation and Steroid Versus Steroid Alone for Relief of Pain in Patients With Advanced Knee and Hip Osteoarthritis

Not Applicable

Recruiting

Conditions: Osteoarthritis, Knee
Osteoarthritis, Hip

Interventions: Procedure: Radiofrequency Ablation (RFA)
Procedure: Perineural Steroid Injection

First Posted Date: 2022-08-05

Last Posted Date: 2024-01-09

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 80

Registration Number: NCT05490355

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy